Biochemistry-first molecular monograph · Version 5.0 · Updated 23 August 2026
TB-500 (Ac-LKKTETQ)
The N-acetylated thymosin-β4 17–23 fragment
The LKKTETQ motif belongs to the actin-related functional region of thymosin-β4 and retains selected activity in defined experimental systems.
This monograph uses TB-500 to denote the N-acetylated heptapeptide Ac-LKKTETQ. It distinguishes that commercial fragment from unacetylated LKKTETQ and from full-length 43-residue thymosin beta-4.
This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.
Epistemological position
The causal chain carries the science.
Identity establishes what exists. Biochemistry establishes what can react. Pharmacology establishes whether the reaction is reachable. Physiology establishes what the system does with it. Statistical human observation comes last and adjudicates only the route, exposure, population and outcome actually studied.
A population average cannot identify a molecule, create a mechanism or decide an individual response. A demonstrated mechanism remains bounded by the causal step shown; a terminal study can confirm or refute its translation under specified conditions, never rewrite the underlying chemistry.
Molecular dossier
The entity before the outcome.
- ENTITY
- N-acetylated heptapeptide Ac-LKKTETQ
- BIOCHEMICAL CLASS
- Thymosin-β4 17–23 fragment
- PRIMARY SYSTEM
- Actin-associated migration · angiogenesis · matrix remodelling
- IDENTITY BOUNDARY
- Ac-LKKTETQ, unacetylated LKKTETQ and full-length 43-residue thymosin-β4 are three distinct entities. Shared motif does not confer shared pharmacokinetics or an identical evidence base.
Action ledger
Describe the action before judging its value.
Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.
Attributed biochemical action
The LKKTETQ motif belongs to the actin-related functional region of thymosin-β4 and retains selected activity in defined experimental systems.
Exposure and reachability
Fragment-specific metabolism has been characterised in vitro and in rats. This does not establish human systemic pharmacokinetics, dose–exposure relationships or clinical target engagement.
Physiological direction is contextual
Actin dynamics, cell migration, angiogenesis and matrix remodelling are necessary components of repair but are not synonymous with high-quality tissue restoration. Spatial organisation, tensile function, inflammatory state and proteolytic balance determine whether greater cellular movement produces useful repair, fibrosis or disordered remodelling.
Individual adjudication boundary
Whether the isolated acetylated fragment reaches and reproduces the parent peptide's spatially organised functions in humans. A full-length thymosin-β4 wound study is not clinical evidence for systemic Ac-LKKTETQ.
Causal map with terminal adjudication
The scientific hierarchy is explicit.
I established for Ac-LKKTETQ; II partial; III predominantly preclinical
The LKKTETQ motif belongs to the actin-related functional region of thymosin-β4 and retains selected activity in defined experimental systems.
Class E for systemic fragment use
This descriptor applies only to the named route, population and outcome. It neither ranks nor creates the molecule’s biochemical science.
Translation boundary
Whether the isolated acetylated fragment reaches and reproduces the parent peptide's spatially organised functions in humans.
What must not be inferred
A full-length thymosin-β4 wound study is not clinical evidence for systemic Ac-LKKTETQ.
Historical and international corpus
Old research is not absent research.
Thymosin biology has been studied since the 1960s and full-length thymosin beta-4 was sequenced in 1981. The commercial Ac-LKKTETQ fragment is a later, distinct chemical entity and cannot inherit the entire historical corpus.
This is where historical depth most easily becomes category error: parent peptide, unacetylated motif and acetylated seven-residue product must remain separated.
Deep thymosin lineage
Thymic fractions preceded isolation and sequencing of distinct alpha and beta thymosins. Full-length thymosin beta-4 was established as a 43-residue N-acetylated peptide, creating a substantial parent-molecule literature.[7]
Actin structure and fragment activity become separable questions
Structural studies mapped extended full-length contacts across actin, while fragment experiments found activity of the LKKTETQ motif in defined endothelial assays. Those records prove relationship but also demonstrate why seven residues cannot reproduce every parent contact.[4][8]
Mechanistic and biochemical calculus
Constraint, measurement and inference are not the same claim.
A biochemical proposition can be powerful without a clinical trial, but its premises, exposure and domain must remain explicit. Each statement below is labelled by the operation that supports it.
Seven residues cannot preserve a 43-residue contact surface
Full-length thymosin beta-4 contacts actin across regions outside LKKTETQ. Removing 36 residues necessarily changes conformational reach even when the retained motif remains active.[7][8]
Motif-level angiogenic activity exists
At the concentrations tested, LKKTETQ supported endothelial migration and sprouting similar to the parent peptide. This is direct fragment biology in an experimental system, not evidence of systemic human efficacy.[4]
Acetylation and systemic exposure remain unbridged
N-terminal acetylation can alter proteolysis and distribution. Without Ac-LKKTETQ-specific human PK, no dose can be mapped rigorously onto the in-vitro activity range.[1][2]
Complete scientific web editionOpen the full causal analysis and referencesThe decision-grade summary remains above. The complete publication stays available here and as a downloadable PDF.
Causal architecture
From molecular event to organismal hypothesis.
Sequence resolution precedes mechanism
Full-length thymosin-β4 folds its 43 residues around actin, whereas TB-500 as defined here contains only the acetylated seven-residue central motif. Removing flanking residues and adding terminal acetylation changes mass, proteolysis and possible molecular contacts.[1][3]
A functional motif can retain partial activity
The LKKTETQ region has shown actin-related, endothelial-migration and wound-model activity in selected experiments. This supports biological continuity with the parent, but continuity is not equivalence: concentration, localisation and conformational reach differ.[4][6]
What is established
✓ Ac-LKKTETQ analytically identified
✓ Distinct from 43-residue thymosin-β4
✓ Fragment metabolism studied preclinically
What remains unresolved
? Human PK
? Direct controlled efficacy
? Systemic safety profile
Causal hierarchy
Seven evidentiary layers. No category substitution.
Levels I-V build the causal and translational model. Human observations and controlled clinical trials then test the complete proposition under the route, exposure, population and outcome actually studied. A trial is terminal adjudication, not the source of molecular truth.
IMolecular identity and chemistryWhat exact sequence, terminal chemistry, formulation and route exist?
IIBiochemistry and target architectureWhat reactions, binding events and signalling steps are physically possible?
IIICells and ex-vivo tissuesWhat changes in the relevant cell or isolated tissue system?
IVAnimal and in-vivo pharmacologyDoes exposure reach the mechanism in an integrated organism?
VIntegrated physiology and translationHow do tissue state, feedback, dose and individual terrain alter the response?
VIHuman PK and observational signalIs the entity present, tolerated and associated with a signal in humans?
VIIControlled clinical trialsDoes the specified protocol change a prespecified patient-relevant outcome?
Method applied to TB-500 (Ac-LKKTETQ)
Where this molecule’s evidence can, and cannot, travel.
The complete corpus-wide attribution rules are published in the scientific methodology. This is their molecule-specific application.
Entity rule applied
Ac-LKKTETQ, unacetylated LKKTETQ and full-length 43-residue thymosin-β4 are three distinct entities. Shared motif does not confer shared pharmacokinetics or an identical evidence base.
Reachability rule applied
Fragment-specific metabolism has been characterised in vitro and in rats. This does not establish human systemic pharmacokinetics, dose–exposure relationships or clinical target engagement. The decisive exposure boundary for TB-500 (Ac-LKKTETQ) therefore remains molecule-, formulation- and route-specific.
Causal-strength rule applied
The LKKTETQ motif belongs to the actin-related functional region of thymosin-β4 and retains selected activity in defined experimental systems. This places the present causal depth at i established for ac-lkktetq; ii partial; iii predominantly preclinical. That grade describes which links in the mechanism have been demonstrated; it is not a consumer rating and cannot be converted into a general promise of benefit.
Human-adjudication rule applied
Class E for systemic fragment use. This terminal descriptor answers only the population, route, exposure and outcome actually observed; it neither upgrades nor cancels a different link in TB-500 (Ac-LKKTETQ)’s causal chain.
Translation rule applied
Whether the isolated acetylated fragment reaches and reproduces the parent peptide's spatially organised functions in humans. A full-length thymosin-β4 wound study is not clinical evidence for systemic Ac-LKKTETQ.
Falsification rule applied
The interpretation must change if any of its decisive propositions fail. For TB-500 (Ac-LKKTETQ), the predeclared tests are: Analytical material inconsistent with Ac-LKKTETQ invalidates the entity attribution. Lack of fragment-specific actin or migration effects would prevent inheritance from parent-peptide biology. Human exposure insufficient for the active experimental range would break systemic translation. These are active boundaries on the conclusion, not research questions appended after a favourable narrative.
Foundational synthesis
Molecular identity and entity resolution
In this monograph TB-500 denotes the N-terminally acetylated 17–23 fragment Ac-LKKTETQ. Full-length thymosin-β4 is a separate 43-residue entity. The terminal acetyl group is part of identity; LKKTETQ alone is incomplete.
Foundational synthesis
Biochemical mechanism and target architecture
Full-length thymosin-β4 regulates actin dynamics, migration, inflammatory signalling, angiogenesis and wound biology. Those mechanisms cannot automatically be assigned to Ac-LKKTETQ.
Foundational synthesis
In-vivo pharmacology and exposure
Fragment-specific metabolism has been characterised in vitro and in rats. This does not establish human systemic pharmacokinetics, dose–exposure relationships or clinical target engagement.
Foundational synthesis
Integrated physiology and individual terrain
Actin dynamics, cell migration, angiogenesis and matrix remodelling are necessary components of repair but are not synonymous with high-quality tissue restoration. Spatial organisation, tensile function, inflammatory state and proteolytic balance determine whether greater cellular movement produces useful repair, fibrosis or disordered remodelling.
Foundational synthesis
Terminal human stress-test
Controlled wound literature concerns defined full-length thymosin-β4 preparations and specific routes. Adequate human evidence for systemic Ac-LKKTETQ administration has not been established.
Foundational synthesis
Counterevidence and causal boundaries
Evidence from full-length thymosin-β4, a preconditioned-cell study or another route is not direct evidence for systemic Ac-LKKTETQ. Sequence and terminal chemistry change degradation and target interaction.
Foundational synthesis
Scientific conclusion
TB-500 requires strict entity resolution. Ac-LKKTETQ and full-length thymosin-β4 cannot share a pharmacokinetic estimate or evidence base merely because commercial language groups them together.
Extended analysis
The identity problem
Full-length thymosin beta-4 is a 43-amino-acid peptide. Its central actin-binding region contains residues 17-23, LKKTETQ. Commercial TB-500 is commonly associated with an N-acetylated version of this fragment. Full-length peptide, unacetylated heptapeptide and Ac-LKKTETQ are structurally distinct entities.[1][3][4]
Terminal acetylation can alter proteolysis, mass and molecular interaction. A study identifying or metabolising Ac-LKKTETQ cannot be silently relabelled as a study of full-length thymosin beta-4, and a full-length wound trial cannot establish systemic efficacy of the fragment.[1][2]
Extended analysis
Actin-binding biology
Full-length thymosin beta-4 forms a 1:1 complex with monomeric actin and helps maintain a reservoir of unpolymerised G-actin. Structural work places contacts across both ends of actin. This is a developed biochemical mechanism for the parent peptide.[3]
The LKKTETQ motif is central to actin-related biology, but the fragment does not necessarily reproduce the conformational reach, intracellular localisation or regulatory functions of the 43-residue parent. A shared motif is evidence of relationship, not evidence of equivalence.[3][4]
Extended analysis
Angiogenesis and matrix remodelling
In endothelial migration and vessel-sprouting assays, the seven-residue actin-binding motif displayed activity similar to full-length thymosin beta-4 at the tested concentrations. This local experimental result supports motif-level angiogenic activity but does not define systemic human exposure or clinical dose.[4]
Full-length thymosin beta-4 and its central domain have also increased matrix-metalloproteinase expression in wound-related cells. Matrix remodelling requires both synthesis and controlled degradation; an increase in MMP expression is therefore a mechanistic event, not automatically an improvement in tissue strength.[5]
Extended analysis
Preclinical wound models
In diabetic and aged mice, full-length thymosin beta-4 accelerated several wound-repair measures. The unacetylated LKKTETQ synthetic peptide produced repair activity in aged animals comparable to the parent in that model. This is important fragment-level evidence, but the studied entity and local model must remain explicit.[6]
A dermal wound outcome in mice cannot establish recovery of a human tendon, muscle, cardiac lesion or neurological injury. Tissue, route, mechanical environment and endpoint all change the translation problem.[5][6]
Extended analysis
Pharmacology and human evidence
Analytical studies have characterised Ac-LKKTETQ and fragment metabolism in vitro and in animals. Human systemic pharmacokinetics, bioavailability, target engagement and immunogenicity have not been adequately established for the commercial fragment.[1][2]
Human wound studies using defined full-length thymosin beta-4 preparations are evidence for those exact preparations and routes. They do not close the evidence chain for systemic Ac-LKKTETQ. At present, there is no adequate controlled human efficacy programme for the entity defined in this monograph.[1][2]
Extended analysis
Scientific conclusion and boundary
The fragment has a biologically meaningful relationship to the parent peptide, supported by actin-binding, angiogenesis and wound-model experiments. The scientific error is not to study the fragment; it is to transfer the parent molecule's full evidence base without resolving sequence, terminal chemistry, route and exposure.[3][4][5][6]
A credible human programme must begin with analytical identity and route-specific PK, then demonstrate target engagement before moving to outcome claims. Until that chain exists, efficacy statements for systemic TB-500 remain conditional rather than established.[1][2]
Evidence atlas
Every claim keeps its experimental address.
12 claim units are mapped to their evidentiary layer, experimental frame and source records. The layer describes what the evidence can answer; it is not a popularity score.
| Layer | Experimental frame | Finding and boundary | Sources |
|---|---|---|---|
| IMolecular identity | The identity problem · claim 1 | Full-length thymosin beta-4 is a 43-amino-acid peptide. Its central actin-binding region contains residues 17-23, LKKTETQ. Commercial TB-500 is commonly associated with an N-acetylated version of this fragment. Full-length peptide, unacetylated heptapeptide and Ac-LKKTETQ are structurally distinct entities. | [1][3][4] |
| IMolecular identity | The identity problem · claim 2 | Terminal acetylation can alter proteolysis, mass and molecular interaction. A study identifying or metabolising Ac-LKKTETQ cannot be silently relabelled as a study of full-length thymosin beta-4, and a full-length wound trial cannot establish systemic efficacy of the fragment. | [1][2] |
| II/VMechanism and physiological translation | Actin-binding biology · claim 1 | Full-length thymosin beta-4 forms a 1:1 complex with monomeric actin and helps maintain a reservoir of unpolymerised G-actin. Structural work places contacts across both ends of actin. This is a developed biochemical mechanism for the parent peptide. | [3] |
| IIICell or ex-vivo system | Actin-binding biology · claim 2 | The LKKTETQ motif is central to actin-related biology, but the fragment does not necessarily reproduce the conformational reach, intracellular localisation or regulatory functions of the 43-residue parent. A shared motif is evidence of relationship, not evidence of equivalence. | [3][4] |
| VIHuman exposure or signal | Angiogenesis and matrix remodelling · claim 1 | In endothelial migration and vessel-sprouting assays, the seven-residue actin-binding motif displayed activity similar to full-length thymosin beta-4 at the tested concentrations. This local experimental result supports motif-level angiogenic activity but does not define systemic human exposure or clinical dose. | [4] |
| VIIControlled human proposition | Angiogenesis and matrix remodelling · claim 2 | Full-length thymosin beta-4 and its central domain have also increased matrix-metalloproteinase expression in wound-related cells. Matrix remodelling requires both synthesis and controlled degradation; an increase in MMP expression is therefore a mechanistic event, not automatically an improvement in tissue strength. | [5] |
| IVIntegrated in-vivo model | Preclinical wound models · claim 1 | In diabetic and aged mice, full-length thymosin beta-4 accelerated several wound-repair measures. The unacetylated LKKTETQ synthetic peptide produced repair activity in aged animals comparable to the parent in that model. This is important fragment-level evidence, but the studied entity and local model must remain explicit. | [6] |
| VIHuman exposure or signal | Preclinical wound models · claim 2 | A dermal wound outcome in mice cannot establish recovery of a human tendon, muscle, cardiac lesion or neurological injury. Tissue, route, mechanical environment and endpoint all change the translation problem. | [5][6] |
| VIHuman exposure or signal | Pharmacology and human evidence · claim 1 | Analytical studies have characterised Ac-LKKTETQ and fragment metabolism in vitro and in animals. Human systemic pharmacokinetics, bioavailability, target engagement and immunogenicity have not been adequately established for the commercial fragment. | [1][2] |
| VIHuman exposure or signal | Pharmacology and human evidence · claim 2 | Human wound studies using defined full-length thymosin beta-4 preparations are evidence for those exact preparations and routes. They do not close the evidence chain for systemic Ac-LKKTETQ. At present, there is no adequate controlled human efficacy programme for the entity defined in this monograph. | [1][2] |
| VIHuman exposure or signal | Scientific conclusion and boundary · claim 1 | The fragment has a biologically meaningful relationship to the parent peptide, supported by actin-binding, angiogenesis and wound-model experiments. The scientific error is not to study the fragment; it is to transfer the parent molecule's full evidence base without resolving sequence, terminal chemistry, route and exposure. | [3][4][5][6] |
| VIHuman exposure or signal | Scientific conclusion and boundary · claim 2 | A credible human programme must begin with analytical identity and route-specific PK, then demonstrate target engagement before moving to outcome claims. Until that chain exists, efficacy statements for systemic TB-500 remain conditional rather than established. | [1][2] |
Methods and coverage
A reproducible boundary, not an implied exhaustive review.
This is a curated mechanistic monograph built from primary records. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.
- SEARCH SURFACE
- PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
- QUERY FRAME
- TB-500 · Ac-LKKTETQ · LKKTETQ · thymosin beta-4 · actin binding · angiogenesis · matrix remodelling
- EVIDENCE CUTOFF
- 23 August 2026
- ENTITY EXCLUSION
- Ac-LKKTETQ, unacetylated LKKTETQ and full-length 43-residue thymosin-β4 are three distinct entities. Shared motif does not confer shared pharmacokinetics or an identical evidence base.
- TRACEABILITY
- 12 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 8 cited records in the complete corpus.
- INTERPRETIVE RULE
- Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.
Falsification map
What could make the proposition wrong?
A scientific monograph must state not only why a mechanism may hold, but what observation would weaken or overturn the inference.
- 01Analytical material inconsistent with Ac-LKKTETQ invalidates the entity attribution.
- 02Lack of fragment-specific actin or migration effects would prevent inheritance from parent-peptide biology.
- 03Human exposure insufficient for the active experimental range would break systemic translation.
Research agenda
What would materially change the conclusion?
A useful research agenda resolves the weakest link in the identity-to-outcome chain. It does not merely add more observations of the same type.
- 01Human PK of analytically confirmed Ac-LKKTETQ
- 02Comparison of acetylated and unacetylated fragments
- 03Direct fragment-versus-full-length target studies
- 04Controlled route-specific human outcomes
- 05Immunogenicity and repeated-dose safety
- 06Matrix quality rather than wound-closure speed alone
Cited primary evidence corpus
8 source records used in this publication.
Reference numbers resolve directly to indexed records. This corpus documents the claims made here; it is not presented as an exhaustive systematic-review search. Index access does not upgrade the evidentiary class of a study.
- [1]Esposito et al. Drug Test Anal. 2012;4:733–738.PMID 22962027 ↗
- [2]Rahaman et al. J Chromatogr B. 2024;1235:124033.PMID 38382158 ↗
- [3]Sanders et al. PNAS. 1992;89:4678–4682.PMID 1584803 ↗
- [4]Malinda et al. The actin-binding site on thymosin beta-4 promotes angiogenesis. J Biol Chem. 2003.PMID 14500546 ↗
- [5]Philp et al. Thymosin beta-4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol. 2006.PMID 16607611 ↗
- [6]Philp et al. Thymosin beta-4 and LKKTETQ promote dermal repair in diabetic and aged mice. Wound Repair Regen. 2003.PMID 12581423 ↗
- [7]Low et al. Complete amino acid sequence of bovine thymosin beta-4. Proc Natl Acad Sci USA. 1981;78:1162–1166.PMID 6940133 ↗
- [8]Safer et al. Thymosin beta-4 binds actin in an extended conformation and contacts both ends. Biochemistry. 1997.PMID 9153421 ↗
Permanent citation
Cite this publication
Wibowo V. TB-500 (Ac-LKKTETQ): Biochemical, Mechanistic and Physiological Monograph. Clinic Terrain Clinical Intelligence Unit. Version 5.0. Updated 23 August 2026.
https://www.clinicterrain.com/research/peptides/tb-500Publication and reference-verification method →Authorship and accountability
Valentine Wibowo, Clinical Researcher, Clinic Terrain Clinical Intelligence Unit, performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent peer review.
No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.